City of Hope National Medical Center, Duarte, CA, USA.
Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Oncologist. 2022 Feb 3;27(1):57-66. doi: 10.1093/oncolo/oyab004.
Diffuse large B-cell lymphoma (DLBCL) is characterized by clinical and molecular heterogeneity; however, this heterogeneity is rarely taken into account by standard-of-care treatment approaches. While the disease was traditionally classified based on transcriptome signatures purporting the tumor cell of origin, recent classification systems have further differentiated these subtypes into clusters based on molecular and genetic features. Alongside a better understanding of the biology of the disease and the signaling pathways involved, emerging therapeutic agents may be better aimed at attacking distinct disease subsets. It is hoped that molecular subtyping at diagnosis will allow patients to be allocated to the appropriate treatment that targets their specific disease subtype, thus advancing the promise of precision medicine in lymphoma, an approach that is most needed. For high-risk disease subsets, this is particularly important, and much research is still needed to develop agents effective in this population. Here, we review recent advances in DLBCL biology and how they can be translated into clinical care.
弥漫性大 B 细胞淋巴瘤（DLBCL）的特征是临床和分子异质性；然而，标准治疗方法很少考虑到这种异质性。虽然该疾病传统上是基于转录组特征进行分类，这些特征表明肿瘤细胞的起源，但最近的分类系统已经根据分子和遗传特征将这些亚型进一步细分为簇。随着对疾病生物学和涉及的信号通路的更好理解，新出现的治疗药物可能更能针对不同的疾病亚群。人们希望在诊断时进行分子分型，以便将患者分配到针对其特定疾病亚型的适当治疗中，从而在淋巴瘤中推进精准医学的承诺，这是最需要的方法。对于高危疾病亚群，这一点尤为重要，因此仍需要大量研究来开发对该人群有效的药物。在这里，我们回顾了 DLBCL 生物学的最新进展，以及如何将其转化为临床护理。
